Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Collaboration › Details

Moderna–Bank of America: investor conference, 201905 supply service Moderna presents at BoAML Global Healthcare Conference in Las Vegas

 

Period Period 2019-05-14
Region Region Las Vegas, NV
  Country United States (USA)
Organisations Partner, 1st Moderna Inc. (Nasdaq: MRNA)
  Group Moderna (Group)
  Partner, 2nd Bank of America Merrill Lynch (BofA Merrill Lynch, marketing name of Bank of America Corporation)
  Group Bank of America (BofA) (Group)
Products Product Bank of America Merrill Lynch Global Healthcare Conference 2019 Las Vegas
  Product 2 mRNA-based drug
Persons Person Zaks, Tal (Moderna Therapeutics 201711 CMO)
  Person 2 Kim, Lorence H. (Moderna 201903 CFO)
     

Moderna, Inc.. (5/6/19). "Press Release: Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference". Cambridge, MA.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT (12:20 p.m. ET).

A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.


About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past four years. To learn more, visit www.modernatx.com.


Moderna Contacts:

Investors:
Lavina Talukdar
Head, Investor Relations
617-209-5834
lavina.talukdar@modernatx.com

Media:
Jason Glashow
Head, Corporate Communications
617-674-5648
Jason.glashow@modernatx.com

   
Record changed: 2019-05-12

Advertisement

Picture [LSBNL] Life-Sciences-Benelux.com – The Business Web Portal 600x86px

More documents for Moderna (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top